Shijiazhuang Yiling Pharmaceutical Co., Ltd. (SHE: 002603)

Market Cap	26.06B
Revenue (ttm)	8.11B
Net Income (ttm)	148.47M
Shares Out	1.67B
EPS (ttm)	0.09
PE Ratio	175.53
Forward PE	19.89
Dividend	0.30 (1.87%)
Ex-Dividend Date	Jul 19, 2024

Volume	20,425,140
Open	16.20
Previous Close	16.31
Day's Range	16.20 - 16.78
52-Week Range	14.37 - 24.47
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 29, 2025

About Shijiazhuang Yiling Pharmaceutical

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of Chinese medicine primarily in China. It offers drugs for respiratory health, cardiovascular disease, diabetes mellitus, oncology, urologic disease, sleep-improving, and anti-aging. The company also provides dietary supplements, health food and drinks, disinfection products, and personal protective equipment, as well as formula granules. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1992
• Employees: 13,958
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002603

Financial Performance

In 2023, Shijiazhuang Yiling Pharmaceutical's revenue was 10.32 billion, a decrease of -17.67% compared to the previous year's 12.53 billion. Earnings were 1.35 billion, a decrease of -42.76%.